inflammatory osteoarthritis
Conditions
Interventions
intercention group:Addition of Topoteb to the original treatment
control group:Oral anti-inflammatory and analgesic drugs
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged over 40 years; 2. The patients should fufill the 1995 ACR osteoarthritis classification criteria; 3. Knee joint swelling, tenderness and increased skin temperature as judged by physicians; 4. Poor response to conventional anti-inflammatory and analgesic drug treatment for 4 weeks; 5. Peripheral erythrocyte sedimentation rate is higher than 28mm/h or high sensitive C reactive protein is over 8mg/L; 6. B-ultrasound or knee MRI clear evidence of synovitis.
Exclusion criteria
Exclusion criteria: 1. IV level of K-L evaluation of knee in X-ray; 2. High level of rheumatoid factor or anti-CCP level(over 2 fold); 3. positive of ANA; 4. Patients with gout, infection or SpA; 5. Positive of TB test; 6. Positive of HBV infection; 7. There is a history of tumor in the past; 8. Patients who are pregnant or breastfeeding; 9. Allergy history of tofacitinib; 10. Abnormal of liver or renal function; 11. The patient had an intra-articular injection of glucocorticoid in the past 12 weeks; 12. Other situation inappropriate to use tofacitinib that decided by researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OMERACT-OARSI;Erythrocyte sedimentation rate;hsCRP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Untralsound evaluation of synovitis;MRI Synovitis Score; | — |
Countries
China
Contacts
Public ContactShengming Dai
Shanghai Sixth People's Hospital
Outcome results
None listed